{
    "clinical_study": {
        "@rank": "63627", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort 5", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort 6", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to evaluate the safety, tolerability and immunogenicity of single, ascending\n      or multiple fixed subcutaneous and intravenous administrations of PF 05335810 to\n      hypercholesterolemic subjects when added on to a daily statin dose."
        }, 
        "brief_title": "A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hypercholesterolemia", 
        "condition_browse": {
            "mesh_term": "Hypercholesterolemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  On stable daily doses of a statin for 45 days prior to receiving study treatment.\n\n          -  Fasting LDL C equal or greater than 80 mg/dL at screening and visit approximately 1\n             week prior to randomization.\n\n        Exclusion Criteria:\n\n          -  History of a cardiovascular or cerebrovascular event or procedure within one year of\n             randomization.\n\n          -  Poorly controlled type 1 or type 2 diabetes mellitus (defined as HbA1c >9%)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "136", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01720537", 
            "org_study_id": "B3091001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cohort 1", 
                "description": "Single SC Injection", 
                "intervention_name": "PF-05335810 Dose A", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "Single Subcutaneous Injection(s)", 
                "intervention_name": "PF-05335810 Dose B", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "Single Subcutaneous Injection(s)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "Single Intravenous Infusion", 
                "intervention_name": "PF-05335810 Dose B", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "Single Intravenous Infusion", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "Single Subcutaneous Injection(s)", 
                "intervention_name": "PF-04950615 Dose A", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "Single Intravenous Infusion", 
                "intervention_name": "PF-04950615 Dose A", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "description": "Single Subcutaneous Injection(s)", 
                "intervention_name": "PF-05335810 Dose C", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "description": "Single Subcutaneous Injection(s)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "description": "Single Intravenous Infusion", 
                "intervention_name": "PF-05335810 Dose C", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "description": "Single Intravenous Infusion", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "description": "Single Subcutaneous Injection(s)", 
                "intervention_name": "PF-04950615", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "description": "Single Subcutaneous Injection(s)", 
                "intervention_name": "PF-05335810 Dose D", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "description": "Single Subcutaneous Injection(s)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Cohort 5", 
                "description": "Multiple fixed dosages administered in subcutaneous injections, monthly for 3 months.", 
                "intervention_name": "PF-05335810 Dose E", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Cohort 6", 
                "description": "Single Intravenous Infusion", 
                "intervention_name": "PF-05335810 Dose D", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Cohort 6", 
                "description": "Single Intravenous Infusion", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "High Cholesterol", 
            "Dyslipidemia"
        ], 
        "lastchanged_date": "November 19, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3091001&StudyName=A%20Study%20To%20Assess%20The%20Safety%20Of%20PF-05335810%20In%20Hypercholesterolemic%20Subjects"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06511"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33169"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "South Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33143"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Overland Park", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66212"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kalamazoo", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "49007"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45227"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78209"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Phase I, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Single, Ascending Doses Of PF-05335810 In Hypercholesterolemic Subjects, With One, Open-Label, Multiple Fixed Dosage Cohort", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to [study drug] was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.", 
                "measure": "Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to Day 85/169 or Early Termination (ET)"
            }, 
            {
                "description": "Pre-defined criteria were established for each laboratory test to define the values that would be identified as of potential clinical importance.", 
                "measure": "Number of Participants With Laboratory Test Values of Potential Clinical Importance", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to Day 85/169 or Early Termination (ET)"
            }, 
            {
                "measure": "Change From Baseline in Heart Rate", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, Day 1 to 85/169 or ET"
            }, 
            {
                "measure": "Diastolic Blood Pressure", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, Day 1 to 85/169 or ET"
            }, 
            {
                "measure": "Change From Baseline in Electrocardiogram (ECG) Parameters", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, Day 1 to 85/169 or ET"
            }, 
            {
                "description": "Pre-defined criteria were established for each laboratory test to define the values that would be identified as of potential clinical importance.", 
                "measure": "Number of Participants With Laboratory Test Values of Potential Clinical Importance", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, Day 1 to 85/169 or ET"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01720537"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).", 
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]", 
                "safety_issue": "No", 
                "time_frame": "Day1 pre-dose to Day 85/169 or ET"
            }, 
            {
                "description": "AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]", 
                "safety_issue": "No", 
                "time_frame": "Day1 pre-dose to Day 85/169 or ET"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Day1 pre-dose to Day 85/169 or ET"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Day1 pre-dose to Day 85/169 or ET"
            }, 
            {
                "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.", 
                "measure": "Apparent Volume of Distribution (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "Day1 pre-dose to Day 85/169 or ET"
            }, 
            {
                "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.  Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling.  Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.", 
                "measure": "Apparent Oral Clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "Day1 pre-dose to Day 85/169 or ET"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Day1 pre-dose to Day 85/169 or ET"
            }, 
            {
                "measure": "Absolute Bioavailability (%F)", 
                "safety_issue": "No", 
                "time_frame": "Day1 pre-dose to Day 85/169 or ET"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}